Table 1 Baseline characteristics of patients after propensity score matching
Variables | Tofacitinib (n = 70) | Abatacept (n = 70) | P |
|---|---|---|---|
Age, years | 69.2 ± 10.1 | 68.6 ± 12.1 | 0.925 |
Female, n, % | 59 (84.3) | 58 (82.9) | 1.000 |
Disease duration, years | 14.8 ± 14.0 | 14.1 ± 13.0 | 0.678 |
Stage I/II/III/IV, % | 20.0/10.0/32.9/37.1 | 25.7/12.9/32.9/28.6 | 0.694 |
Class 1/2/3/4, % | 5.7/71.4/22.9/0.0 | 5.7/68.6/25.7/0.0 | 0.956 |
BMI, kg/m2 | 21.4 ± 3.3 | 21.8 ± 2.8 | 0.505 |
SE copy number 0/1/2, % | 31.4/61.4/7.1 | 28.6/54.3/17.1 | 0.252 |
Current smoker, n (%) | 4 (5.7) | 5 (7.1) | 1.000 |
Ever smoker, n (%) | 14 (20.0) | 21 (30.0) | 0.241 |
No. of prior biologic use | |||
 0 (biologic naïve ) | 31 | 37 | 0.398 |
 1 | 13 | 14 | 0.830 |
 2 | 14 | 7 | 0.098 |
  ≥ 3 | 12 | 12 | 1.00 |
MTX use, n (%) | 41 (58.6) | 40 (57.1) | 1.000 |
MTX dose, mg/week | 8.4 ± 2.4 | 8.0 ± 2.7 | 0.441 |
Oral corticosteroid use, n (%) | 27 (38.6) | 24 (34.3) | 0.726 |
Oral corticosteroid dose, mg/daya | 4.5 ± 2.8 | 5.5 ± 3.9 | 0.288 |
MMP-3, ng/mL | 243.6 ± 242.9 | 153.4 ± 134.6 | 0.140 |
SJC, 0–28 | 4.4 ± 4.1 | 3.7 ± 3.7 | 0.507 |
TJC, 0–28 | 5.9 ± 5.0 | 5.4 ± 5.3 | 0.557 |
ESR, mm/h | 40.1 ± 32.0 | 38.2 ± 30.2 | 0.882 |
CRP, mg/dL | 1.54 ± 1.92 | 1.48 ± 2.19 | 0.742 |
RF, U/mL | 217.7 ± 529.9 | 165.1 ± 375.8 | 0.790 |
ACPA, U/mL | 245 ± 393.3 | 256.6 ± 293.8 | 0.323 |
GH, VAS 0–100 mm | 53.1 ± 28.4 | 52.2 ± 24.2 | 0.777 |
EGA, VAS 0–100 mm | 47.8 ± 20.4 | 45.2 ± 15.8 | 0.522 |
SDAI | 21.9 ± 12.1 | 20.3 ± 11.4 | 0.283 |
CDAI | 20.3 ± 11.2 | 19.8 ± 10.0 | 0.326 |
DAS28-ESR | 4.8 ± 1.4 | 4.7 ± 1.3 | 0.508 |
HAQ-DI | 1.12 ± 0.81 | 1.07 ± 0.76 | 0.689 |